Browsing by Author "n 89200647"

Now showing items 21-40 of 54

    • Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. 

      Altarawneh, Heba N; Chemaitelly, Hiam; Ayoub, Houssein H; Tang, Patrick; Hasan, Mohammad R; ... more authors ( Massachusetts Medical Society , 2022 , Article)
      The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) ...

    • Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study 

      Heba N., Altarawneh; Chemaitelly, Hiam; Ayoub, Houssein H.; Tang, Patrick; Hasan, Mohammad R.; ... more authors ( Elsevier , 2023 , Article)
      BackgroundProtection against SARS-CoV-2 symptomatic infection and severe COVID-19 of previous infection, mRNA two-dose vaccination, mRNA three-dose vaccination, and hybrid immunity of previous infection and vaccination ...

    • Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections 

      Qassim, Suelen H.; Hasan, Mohammad R.; Tang, Patrick; Chemaitelly, Hiam; Ayoub, Houssein H.; ... more authors ( Frontiers Media , 2022 , Article)
      In 2021, Qatar experienced considerable incidence of SARS-CoV-2 infection that was dominated sequentially by the Alpha, Beta, and Delta variants. Using the cycle threshold (Ct) value of an RT-qPCR-positive test to proxy ...

    • Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: Mathematical modelling analyses 

      Ayoub, H.H.; Ayoub, Houssein H.; Chemaitelly, Hiam; Makhoul, Monia; Al Kanaani, Zaina; ... more authors ( BMJ Publishing Group , 2021 , Article)
      Background Vaccines against SARS-CoV-2 have been developed, but their availability falls far short of global needs. This study aimed to investigate the impact of prioritising available doses on the basis of recipient ...

    • Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February-18 April 2020 

      Al Kuwari, Hanan M.; Abdul Rahim, Hanan F.; Abu-Raddad, Laith J.; Abou-Samra, Abdul Badi; Al Kanaani, Zaina; ... more authors ( BMJ Publishing Group , 2020 , Article)
      © Authors 2020 Objective To define the epidemiological curve of COVID-19 in Qatar and determine factors associated with severe or critical illness. Design Case series of first 5685 COVID-19 cases in Qatar. Setting and ...

    • Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design. 

      Ayoub, Houssein H; Tomy, Milan; Chemaitelly, Hiam; Altarawneh, Heba N; Coyle, Peter; ... more authors ( Oxford University Press , 2023 , Article)
      The COVID-19 pandemic has highlighted the need to use infection testing databases to rapidly estimate effectiveness of prior infection in preventing reinfection ($P{E}_S$) by novel SARS-CoV-2 variants. Mathematical modeling ...

    • History of primary-series and booster vaccination and protection against Omicron reinfection 

      Chemaitelly, Hiam; Ayoub, Houssein H.; Tang, Patrick; Coyle, Peter V.; Yassine, Hadi M.; ... more authors ( American Association for the Advancement of Science , 2023 , Article)
      Laboratory evidence suggests a possibility of immune imprinting for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We investigated the differences in the incidence of SARS-CoV-2 reinfection in a ...

    • Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2 

      Chemaitelly, Hiam; Ayoub, Houssein H.; Tang, Patrick; Hasan, Mohammad R.; Coyle, Peter; ... more authors ( Massachusetts Medical Society , 2022 , Other)
      More than 2 years into the coronavirus disease 2019 (Covid-19) pandemic, the global population carries heterogeneous immune histories derived from various exposures to infection, viral variants, and vaccination.1 Evidence ...

    • Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study 

      J. Abu-Raddad, Laith; Chemaitelly, Hiam; H. Ayoub, Houssein; Coyle, Peter; A. Malek, Joel; ... more authors ( Public Library of Science , 2021 , Article)
      Background The epidemiology of the SARS-CoV-2 B.1.1.7 (or Alpha) variant is insufficiently understood. This study’s objective was to describe the introduction and expansion of this variant in Qatar and to estimate the ...

    • Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study 

      Hiam, Chemaitelly; Ayoub, Houssein H; Tang, Patrick; Coyle, Peter; Yassine, Hadi M; ... more authors ( Elsevier , 2023 , Article)
      BackgroundLong-term effectiveness of COVID-19 mRNA boosters in populations with different previous infection histories and clinical vulnerability profiles is inadequately understood. We aimed to investigate the effectiveness ...

    • Mathematical modeling of the SARSCoV-2 epidemic in Qatar and its impact on the national response to COVID-19 

      Ayoub, Houssein H.; Chemaitelly, Hiam; Seedat, Shaheen; Makhoul, Monia; Kanaani, Zaina Al; ... more authors ( University of Edinburgh , 2021 , Article)
      Background Mathematical modeling constitutes an important tool for planning robust responses to epidemics. This study was conducted to guide the Qatari national response to the severe acute respiratory syndrome coronavirus ...

    • mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar 

      Chemaitelly, Hiam; Yassine, Hadi M.; Benslimane, Fatiha M.; Al Khatib, Hebah A.; Tang, Patrick; ... more authors (2021 , Article)
      The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a ...

    • A new One Health Framework in Qatar for future emerging and re-emerging zoonotic diseases preparedness and response 

      Devendra, Bansal; Jaffrey, Shariq; Al-Emadi, Noora Abdulla; Hassan, Mahmoud; Islam, Md. Mazharul; ... more authors ( Elsevier , 2023 , Article)
      One Health is increasingly recognized as an optimal approach to address the global risk of health threats originating at the human, animal, and ecosystem interface, and their impact. Qatar has successfully practiced One ...

    • One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar 

      Benslimane, Fatiha M; Al Khatib, Hebah A; Al-Jamal, Ola; Albatesh, Dana; Boughattas, Sonia; ... more authors ( Frontiers , 2021 , Article)
      Qatar, a country with a strong health system and a diverse population consisting mainly of expatriate residents, has experienced two large waves of COVID-19 outbreak. In this study, we report on 2634 SARS-CoV-2 whole-genome ...

    • Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. 

      Abu-Raddad, Laith J; Chemaitelly, Hiam; Yassine, Hadi M; Benslimane, Fatiha M; Al Khatib, Hebah A; ... more authors ( Oxford University Press , 2021 , Article)
      Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across countries. A key question is whether delaying administration of the second vaccine dose to vaccinate the largest number of ...

    • Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study 

      Suelen H., Qassim; Chemaitelly, Hiam; Ayoub, Houssein H.; Coyle, Peter; Tang, Patrick; ... more authors ( Elsevier , 2023 , Article)
      BackgroundWaning of natural infection protection and vaccine protection highlight the need to evaluate changes in population immunity over time. Population immunity of previous SARS-CoV-2 infection or of COVID-19 vaccination ...

    • Protection against Reinfection with the Omicron BA.2.75 Subvariant 

      Chemaitelly, Hiam; Tang, Patrick; Coyle, Peter; Yassine, Hadi M.; Al-Khatib, Hebah A.; ... more authors ( Massachusetts Medical Society , 2023 , Other)
      The BA.2.75 sublineage of the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may escape neutralizing antibodies. The BA.2.75 sublineage (primarily the BA.2.75.2 subvariant) ...

    • Protection against the omicron variant from previous SARS-CoV-2 infection 

      Altarawneh, Heba N.; Chemaitelly, Hiam; Hasan, Mohammad R.; Ayoub, Houssein H.; Qassim, Suelen; ... more authors ( Massachusetts Medical Society , 2022 , Other)
      Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha),1,2 B.1.351 (beta),1 and B.1.617.2 (delta)3 variants. However, the ...

    • Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study 

      Hiam, Chemaitelly; Ayoub, Houssein H; AlMukdad, Sawsan; Coyle, Peter; Tang, Patrick; ... more authors ( Elsevier , 2022 , Article)
      BackgroundUnderstanding protection conferred by natural SARS-CoV-2 infection versus COVID-19 vaccination is important for informing vaccine mandate decisions. We compared protection conferred by natural infection versus ...

    • Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage 

      Chemaitelly, Hiam; Ayoub, Houssein H.; Coyle, Peter; Tang, Patrick; Yassine, Hadi M.; ... more authors ( Nature Research , 2022 , Article)
      There is significant genetic distance between SARS-CoV-2 Omicron (B.1.1.529) variant BA.1 and BA.2 sub-lineages. This study investigates immune protection of infection with one sub-lineage against reinfection with the other ...